Astrana Health, Inc. (ASTH) and Ensign Group (ENSG) on Torvanta's measures: ASTH grades higher on 1 of the 4 factor families and ENSG on 2.
| ASTH | ENSG | |
|---|---|---|
| Value grade | C+ | C+ |
| Growth grade | B | B- |
| Profitability grade | C- | C+ |
| Momentum grade | C- | C |
| Market value | $2.1B | $10.3B |
| P/E (trailing) | 44.3x | 27.7x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $3.8B | $5.5B |
| Revenue growth (y/y) | +59% | +19% |
| Operating margin | 2.6% | 8.5% |
| Return on invested capital | 4.8% | 15.3% |
| Free-cash-flow yield | 4.6% | 5.9% |
| Total return, 1 year | +15.8% | -1.4% |
| Total return, 3 years | n/a | n/a |
Full ASTH analysis · Full ENSG analysis
Astrana Health, Inc. (ASTH) and Ensign Group (ENSG) on Torvanta's measures: ASTH grades higher on 1 of the 4 factor families and ENSG on 2. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings ASTH trades at 44.3x and ENSG at 27.7x; their value grades are C+ and C+ against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer